Table 1.
Characteristics of children by intervention group, sulforaphane (SF) or placebo (PL), at baseline
| Characteristic | SF (n = 22) | PL (n = 23) | p valuea |
|---|---|---|---|
| Age (years), mean (SD) | 7.4 (3.0) | 7.0 (2.5) | 0.62 |
| Male sex, n (%) | 20 (90.9) | 20 (90.0) | 0.67 |
| Race, n (%) | 0.37 | ||
| White | 17 (77.3) | 15 (65.2) | |
| Otherb | 5 (22.7) | 8 (34.8) | |
| BMI (kg/m2), mean (SD) | 16.6 (3.1) | 17.4 (3.6) | 0.44 |
| Fever responder, n (%) | 11 (50.0) | 8 (34.8) | 0.30 |
| Regression, n (%) | 10 (45.5) | 6 (26.1) | 0.18 |
| Concomitant medications or therapy, n (%) | 2 (9.1) | 5 (21.7) | 0.24 |
| ADOS-2 Calibrated Severity Score, mean (SD) | 7.9 (1.4) | 7.4 (1.4) | 0.31 |
| ADOS-2 social affect score, mean (SD) | 13.7 (3.8) | 11.8 (3.7) | 0.14 |
| ADOS-2 repetitive behaviors score, mean (SD) | 4.7 (1.6) | 5.7 (1.5) | 0.06 |
| Baseline SRS-2 total raw score, mean (SD) | 118.2 (26.7) | 115.3 (16.6) | 0.66 |
| Baseline ABC total score, mean (SD) | 74.2 (30.5) | 59.7 (23.6) | 0.08 |
| Baseline OACIS-S general level of ASD symptoms/behaviors | 0.26 | ||
| Mild/moderate, n (%) | 7 (31.8) | 7 (30.4) | |
| Marked, n (%) | 7 (31.8) | 12 (52.2) | |
| Severe, n (%) | 8 (36.4) | 4 (17.4) | |
| Baseline overall Vineland scorec | 57.5 (11.9) | 57.6 (6.7) | 0.98 |
| Baseline Leiter composite IQ Scorec | 70.4 (30.8) | 70.8 (22.1) | 0.96 |
BMI body mass index, SRS-2 social responsiveness scale 2, ABC Aberrant Behavior Checklist, OACIS-S Ohio Autism Clinical Impressions Scale (or clinical global impression)—severity, ASD autism spectrum disorders, IQ intelligence quotient
aChi-square for binary or categorical variables; t test for continuous variables
bOther race includes Asian, mixed or unknown
cN = 18 for SF group, N = 22 for PL group